Clinical Trial Search

Primary: Evaluate the Efficacy of RBT-1 in Generating a Preconditioning Response as Measured by a Composite of Biomarkers — 3.60; 2.63; 1.00 composite ratio — p=<0.0001

Primary: Maximum Tolerated Dose (MTD) [Phase I Dose Escalation] — 5 mg

Primary: Number of Participants With Dose Limiting Toxicity (DLT) [Phase 1b] — 0 Participants

Primary: Progression-free Survival — 11.5 months

Primary: Number of Participants With Biopsy Results Correlated With PET Based Imaging Findings — 13; 13 Participants

Primary: Number of Subjects With Progression Free Survival — 6 Participants

Primary: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 58.3; 10.5 percentage

Primary: Part A, Phase I — 0; 1; 3; 0 Participants

Primary: Number of Patients With Biliary Atresia (BA) Achieving Total Serum Bile Acids Less Than or Equal to 10 *U*Mol/L Within 24 Weeks of Kasai Portoenterostomy (KP) — 0…

Primary: Number of Conversions of Non-inflamed to Inflamed Melanoma — 3; 7 Participants

Primary: Phase 2: Progression Free Survival (PFS), as Determined by the Local Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) — 1.51…

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants

Primary: Progression Free Survival (PFS) — 4.8 months

Primary: Change in Symptom Scores Induced by the Rhinovirus Using Jackson Criteria Including Nasal Congestion, Drainage, Cough, Wheezing — 5.0; 4.2; 2.8 score on a scale

Primary: Change From Baseline in Smell Identification Test Score at 6 Weeks — 4 units on a scale